|
WO2016071890A1
|
|
Theranostic method for optimizing the choice of an immune checkpoint blocker to be administered to a cancer patient
|
|
WO2015162596A1
|
|
Use of immune diversity as a predictive marker for identifying patients likely to respond to an anti-ctla4 treatment
|
|
US2016068905A1
|
|
Method for Studying V(D)J Combinatory Diversity
|
|
EP2975137A1
|
|
Use of immune diversity as a predictive marker for identifying B-cell-lymphomas-patients having an increased risk of febrile or infectious event
|
|
EP2937698A1
|
|
Use of immune combinatorial diversity as a predictive marker for identifying patients likely to respond to an anti-CTLA-4 treatment
|
|
EP2333106A1
|
|
Use of the combinatory diversity of the catalogue of T lymphocytes as a cancer prognostic marker
|
|
EP2062982A1
|
|
Method for studying the V(D)J combinatorial diversity.
|
|
EP1981975A2
|
|
Composition for stabilizing biological samples and method of stabilization
|
